Floatz logo

AXUMIN

Prostate Carcinoma

NRG OncologySmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

107 Active assets in the Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Leuporelin
Mayo Clinic
Phase 4BBB
Prednisone
Mayo Clinic
Phase 4BBB
Enzalutamide
Pfizer
Phase 4BBB
Degarelix
Baptist Health South Florida
Phase 3BBB
Abiraterone
Mayo Clinic
Phase 4BBB

View all 49 →

Same molecule, other indications

AXUMIN is also rated in:

metastatic prostate carcinomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative · Phase 4
65 / 100
View asset →
prostate cancerActive
B
Indicative · Phase 4
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →